FOR IMMEDIATE RELEASE
Dr. Block honored for discovery of molecular mechanisms of viral persistence
and therapeutic strategies for Hepatitis B
Doylestown, PA, March 2009 – The Hepatitis B Foundation is proud to announce the induction of Dr. Timothy Block, co-founder and president of the Hepatitis B Foundation, as an AAAS Fellow this year. He joins an elite rank of scientists who are elected annually by the American Association for the Advancement of Science (AAAS). Since 1874, the AAAS has elected Fellows from around the world whose distinguished efforts have have significantly advanced science or been of extraordinary distinction. Dr. Block was honored for his discovery of molecular mechanisms of viral persistence and therapeutic strategies for hepatitis B virus and herpes simplex virus.
In 1991, Dr. Block co-founded the Hepatitis B Foundation to lead the fight against this deadly viral infection. Today, the Foundation is the only national nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the lives of those affected worldwide through research, education and patient advocacy. Dr. Block has been involved in chronic viral hepatitis research for more than 20 years and is internationally recognized for his outstanding scholarship and scientific contributions.
Dr. Block is also a Professor of Microbiology and Immunology, Drexel University College of Medicine, and Director of the Drexel Institute for Biotechnology and Virology Research. Dr. Block is Chair, Gastroenterology Extramural Collaborative Groups of the cancer prevention section of the National Cancer Institute; serves on NIH study sections; is an elected Fellow, International Union Against Cancer; elected Fellow, Glycobiology Institute of The University of Oxford; and recipient of many awards and patents for his scientific achievements.
About the Hepatitis B Foundation
The Hepatitis B Foundation is the only national nonprofit organization solely dedicated to finding a cure and improving the quality of life for those affected with hepatitis B worldwide through research, education and patient advocacy. The Foundation is headquartered at the Pennsylvania Biotechnology Center, which it created to advance and accelerate its research mission. For more information, please call 215-489-4900 or visit www.hepb.org.
Page last modified March 30, 2009